Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone in boys with Duchenne muscular dystrophy
NCT02760264Phase 2Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Jun 2016
- Primary completion
- May 2018
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by ReveraGen BioPharma. Started Jun 2016; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02760264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760264.